Posted inHematology-Oncology news Oncology
Targeting IGF2BP2: A Novel Therapeutic Avenue in Peripheral T-cell Lymphoma Through RNA Modification and Immune Modulation
This article explores the pivotal role of IGF2BP2, an N6-methyladenosine reader, in driving tumor growth and immune evasion in peripheral T-cell lymphoma, highlighting its potential as a dual-action therapeutic target.
